Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million (USD 6.3 million) to acquire a 4.7% stake in Shanghai Apactron Particle Equipment Co., Ltd., a company specializing in high-end particle therapy technology. This strategic deal is aimed at leveraging Apactron’s expertise in proton therapy systems.
Apactron’s Proton Therapy System and National Significance
Founded in 2011, Apactron is recognized for developing China’s first home-grown proton therapy system, which was approved for marketing in 2022 as part of a national key support program. The system is composed of two main components: an accelerator system and a treatment system. The accelerator system includes an injector system, a low energy transmission system, a main accelerator system, a high-energy beam transmission system, and an auxiliary electrical system. The treatment system comprises a fixed beam treatment system, a 180° rotating beam treatment system, and a treatment planning system.
Therapeutic Benefits and Applications of Proton Beam Radiation Therapy
Proton beam radiation therapy offered by Apactron’s product can reduce the dose to surrounding normal tissues, particularly those behind the target area, while delivering high doses to the tumor site. This precision is particularly beneficial for treating solid malignant tumors and certain benign diseases throughout the body. Clinical physicians determine the specific indications based on the patient’s actual condition.-Fineline Info & Tech